Works matching IS 27525481 AND DT 2022 AND VI 18 AND IP 2
Results: 11
Trilaciclib: A First-in-class Therapy to Reduce Chemotherapy-induced Myelosuppression.
- Published in:
- touchREVIEWS in Oncology & Haematology, 2022, v. 18, n. 2, p. 152, doi. 10.17925/OHR.2022.18.2.152
- By:
- Publication type:
- Article
Oral Therapies for Multiple Myeloma.
- Published in:
- touchREVIEWS in Oncology & Haematology, 2022, v. 18, n. 2, p. 139, doi. 10.17925/OHR.2022.18.2.139
- By:
- Publication type:
- Article
Advances and Future Goals in Acute Myeloid Leukaemia Therapy.
- Published in:
- touchREVIEWS in Oncology & Haematology, 2022, v. 18, n. 2, p. 130, doi. 10.17925/OHR.2022.18.2.130
- By:
- Publication type:
- Article
Clinical Utility of Human Papillomavirus Circulating Tumour DNA in Human Papillomavirus-positive Head and Neck Squamous Cell Carcinomas.
- Published in:
- touchREVIEWS in Oncology & Haematology, 2022, v. 18, n. 2, p. 125, doi. 10.17925/OHR.2022.18.2.125
- By:
- Publication type:
- Article
Is Triple Therapy the New Standard for Metastatic Hormone-sensitive Prostate Cancer?
- Published in:
- touchREVIEWS in Oncology & Haematology, 2022, v. 18, n. 2, p. 120, doi. 10.17925/OHR.2022.18.2.120
- By:
- Publication type:
- Article
Frontiers in Non-metastatic, Muscle-invasive Bladder Cancer.
- Published in:
- touchREVIEWS in Oncology & Haematology, 2022, v. 18, n. 2, p. 113, doi. 10.17925/ohr.2022.18.2.113
- By:
- Publication type:
- Article
Targets, Therapies and the Role of Serial Biopsies for Prognostication and Assessing Changes to Tumour Biology in Oesophageal and Oesophagogastric Junction Cancers.
- Published in:
- touchREVIEWS in Oncology & Haematology, 2022, v. 18, n. 2, p. 107, doi. 10.17925/OHR.2022.18.2.107
- By:
- Publication type:
- Article
Treatment Options in BRAF-mutant Metastatic Colorectal Cancer.
- Published in:
- touchREVIEWS in Oncology & Haematology, 2022, v. 18, n. 2, p. 103, doi. 10.17925/OHR.2022.18.2.103
- By:
- Publication type:
- Article
Management of Metastatic Triple-negative Breast Cancer: Focus on Targeted Therapies.
- Published in:
- touchREVIEWS in Oncology & Haematology, 2022, v. 18, n. 2, p. 98, doi. 10.17925/OHR.2022.18.2.98
- By:
- Publication type:
- Article
ATLAS: Risk-adapted Triplet Maintenance with Carfilzomib, Lenalidomide and Dexamethasone - Still Shrugging?
- Published in:
- touchREVIEWS in Oncology & Haematology, 2022, v. 18, n. 2, p. 96, doi. 10.17925/OHR.2022.18.2.96
- By:
- Publication type:
- Article
Foreword.
- Published in:
- touchREVIEWS in Oncology & Haematology, 2022, v. 18, n. 2, p. 1
- By:
- Publication type:
- Article